Meanwhile, DeepTEPP-High patients receiving dual HER2 blockade had substantially improved RFS compared to those treated with trastuzumab alone (2y-RFS 67.7% vs 100.0%, p = 0.045; Fig. 3D), indicating DeepTEPP was capable of risk stratification and could guide adjuvant anti-HER2 target treatment strategy in early HER2-positive breast cancer patients (Fig. 2). Here, ERBB2 is linked to breast carcinoma.